Vigil Neuroscience Inc (VIGL) Stock Price, Quote & News

Company Profile

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company's lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids a...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 254 4445

Website: www.vigilneuro.com

Address:

100 Forge Road, Suite 700 Watertown, Watertown, United States

Norbert90 Jul. 9 at 3:22 PM

$VIGL No more free CVRs.

1 · Reply

BioTechHealthX Jul. 6 at 5:30 PM

$VIGL Learn why Sanofi’s $600M acquisition of Vigil Neuroscience could signal a shift in Alzheimer’s treatment. VIGL may still have room to run. https://biotechhealthx.com/biotech-news/vigil-neuroscience-vigl-the-tiny-biotech-sanofi-just-bet-600m-on/

1 · Reply

junglezoo Jul. 6 at 3:41 PM

$NKGN $VIGL

0 · Reply

Norbert90 Jul. 2 at 1:23 PM

$VIGL Third and final quarter. Any updates on timeline for the deal closing?

1 · Reply

Joe_088 Jul. 2 at 1:21 PM

$DWTX $VIGL $WINT 3 stock was 💎💎💎

0 · Reply

Ridiculous78 Jun. 26 at 10:24 PM

$VIGL Made some good money here. You will be missed 👍🏼

0 · Reply

Stocks4thought Jun. 26 at 11:10 AM

$TCRX Its another $SGMT OR $VIGL - they drive them deep and then algo-s build tremendous wealth. Saw it with $SLNO cost basis $3.42. GO Figure or Go f the traders.

0 · Reply

BinaryLogic Jun. 26 at 2:38 AM

$VTYX $RGLS $VIGL

0 · Reply

GreylockSec Jun. 23 at 11:08 PM

$TPST ....A nice little buyout from this past May from Sanofi that sort of went under the radar, yet still brings a bit of fresh hopium into the small-cap biotech world.... ...Sanofi bought only one of two therapies developed by $VIGL Vigil, being its lead, stage-2-ready, Alzheimer's candidate (a TREM-2 protein that shows up on immune cells in the brain, and still remains a mostly uncharted target) for a whopping $470 million in cash (or $8/share) and another $2 worth of CVRs should the therapy progress...A big payout for a Stage-1 (potential) therapy. ....Small, Stage-1 experimental therapy buyouts like this one by big-pharma help to shape the appearance of a rising biotech comeback with such forward-thinking investments already this year. Thank God Brady knows his science.

0 · Reply

Stocks4thought Jun. 23 at 1:49 PM

$ANIX $SGMT $VIGL it works https://nypost.com/2025/06/07/us-news/breakthrough-vaccine-could-eradicate-breast-cancer-by-2030/

0 · Reply

VIGIL NEUROSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Vigil Neuroscience, Inc. - VIGL

SNY

Jun 4, 2025, 7:00 AM EDT - 5 weeks ago

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

May 21, 2025, 7:59 PM EDT - 7 weeks ago

Sanofi to Buy Vigil Neuroscience for About $470 Million

SNY

May 21, 2025, 7:30 PM EDT - 7 weeks ago

Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi

SNY

May 21, 2025, 7:29 PM EDT - 7 weeks ago

Sanofi to acquire Vigil Neuroscience in $470 million deal

SNY

May 21, 2025, 7:15 PM EDT - 7 weeks ago

Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline

SNY

May 7, 2025, 7:00 AM EDT - 2 months ago

Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates

Apr 2, 2025, 7:00 AM EDT - 3 months ago

Vigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International Conference

Mar 13, 2025, 7:00 AM EDT - 4 months ago

Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Mar 11, 2025, 7:00 AM EDT - 4 months ago

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum

Jan 30, 2025, 7:00 AM EST - 5 months ago

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

Jan 23, 2025, 11:33 AM EST - 6 months ago

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

Jan 23, 2025, 7:00 AM EST - 6 months ago

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease

Jan 8, 2025, 4:05 PM EST - 6 months ago

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

Sep 17, 2024, 7:00 AM EDT - 10 months ago

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

Sep 16, 2024, 4:05 PM EDT - 10 months ago

Vigil Neuroscience to Present at Cantor Global Healthcare Conference

Aug 29, 2024, 7:00 AM EDT - 11 months ago

Vigil Neuroscience to Present at Upcoming September Investor Conferences

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 24, 2024, 7:00 AM EDT - 1 year ago

Vigil Neuroscience Announces Interim Data from its Ongoing Phase 1 Clinical Trial Evaluating VG-3927 in Healthy Volunteers Supporting Continued Development in Alzheimer's Disease

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Vigil Announces Upcoming Presentations on its Small Molecule TREM2 Agonist VG-3927 at the 2024 Alzheimer's Association International Conference

Jul 18, 2024, 7:00 AM EDT - 1 year ago

Vigil Neuroscience Provides Update on Clinical Development Strategy to Pursue Potential Accelerated Approval Pathway for Iluzanebart in ALSP

Jun 27, 2024, 2:00 AM EDT - 1 year ago

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

Jun 26, 2024, 1:00 AM EDT - 1 year ago

Augustine Therapeutics Raises EUR 17 Million in a Series A First Closing to Advance Lead Candidate Into Clinical Development in Neurological Diseases

May 30, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience to Present in Upcoming June Investor Conferences

May 8, 2024, 7:40 AM EDT - 1 year ago

Vigil Neuroscience to Present at The Citizens JMP Life Sciences Conference

May 7, 2024, 4:05 PM EDT - 1 year ago

Vigil Neuroscience Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 17, 2024, 4:05 PM EDT - 1 year ago

Vigil Presents Key Findings from ILLUMINATE & IGNITE Studies in ALSP at the 2024 American Academy of Neurology Annual Meeting

Mar 26, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 20, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

Mar 13, 2024, 7:05 AM EDT - 1 year ago

Vigil Announces Upcoming Presentations at 2024 American Academy of Neurology Annual Meeting

Mar 12, 2024, 7:05 AM EDT - 1 year ago

Vigil Neuroscience to Present at Stifel 2024 Virtual CNS Days

Mar 6, 2024, 4:25 PM EST - 1 year ago

Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024

Feb 29, 2024, 4:05 PM EST - 1 year ago

Vigil Presents Poster on Impacts of Misdiagnosis and Genetic Testing on Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Patient Journey at ACTRIMS 2024

Feb 7, 2024, 4:05 PM EST - 1 year ago

Vigil Neuroscience to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 3, 2024, 4:30 PM EST - 1 year ago

Vigil Neuroscience Provides 2023 Year-in-Review and Highlights Upcoming 2024 Milestones

Nov 22, 2023, 4:05 PM EST - 1 year ago

Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference

Nov 20, 2023, 7:34 PM EST - 1 year ago

Vigil Neuroscience: Interim Data Sheds Light On Possible Accelerated Pathway

Nov 16, 2023, 4:05 PM EST - 1 year ago

Vigil Neuroscience Reports Positive Interim Data from Phase 2 IGNITE Proof-of-Concept Clinical Trial Evaluating Iluzanebart (VGL101) as a Treatment for ALSP and from Ongoing Natural History Study ILLUMINATE

Nov 7, 2023, 7:05 AM EST - 1 year ago

Vigil Neuroscience Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 17, 2023, 7:05 AM EDT - 1 year ago

Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer's Disease

Oct 5, 2023, 4:01 PM EDT - 1 year ago

Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit

Sep 26, 2023, 7:05 AM EDT - 1 year ago

Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP

Sep 18, 2023, 2:38 PM EDT - 1 year ago

Vigil Neuroscience: Interesting Early Data, Wait For Phase 2

Sep 11, 2023, 12:00 PM EDT - 2 years ago

Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting

Sep 8, 2023, 4:05 PM EDT - 2 years ago

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

Sep 8, 2023, 7:05 AM EDT - 2 years ago

Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference

Norbert90 Jul. 9 at 3:22 PM

$VIGL No more free CVRs.

1 · Reply

BioTechHealthX Jul. 6 at 5:30 PM

1 · Reply

junglezoo Jul. 6 at 3:41 PM

$NKGN $VIGL

0 · Reply

Norbert90 Jul. 2 at 1:23 PM

$VIGL Third and final quarter. Any updates on timeline for the deal closing?

1 · Reply

Joe_088 Jul. 2 at 1:21 PM

$DWTX $VIGL $WINT 3 stock was 💎💎💎

0 · Reply

Ridiculous78 Jun. 26 at 10:24 PM

$VIGL Made some good money here. You will be missed 👍🏼

0 · Reply

Stocks4thought Jun. 26 at 11:10 AM

$TCRX Its another $SGMT OR $VIGL - they drive them deep and then algo-s build tremendous wealth. Saw it with $SLNO cost basis $3.42. GO Figure or Go f the traders.

0 · Reply

BinaryLogic Jun. 26 at 2:38 AM

$VTYX $RGLS $VIGL

0 · Reply

GreylockSec Jun. 23 at 11:08 PM

0 · Reply

Stocks4thought Jun. 23 at 1:49 PM

$ANIX $SGMT $VIGL it works https://nypost.com/2025/06/07/us-news/breakthrough-vaccine-could-eradicate-breast-cancer-by-2030/

0 · Reply

Quantumup Jun. 23 at 12:03 PM

Canaccord Genuity reiterated $VTYX Buy-$14 after Ventyx reported positive results from the Phase lla open-label study for VTX3232 in early Parkinson's disease (PD). $VIGL - $SNY Canaccord Genuity said in its note; "The trial's positive results demonstrated effective inhibition of NLRP3 and suppression of downstream biomarkers. Results from the trial support once-daily dosing. Ventyx plans to initiate a Phase II dose-ranging study for the drug in patients with Parkinson's. We are encouraged by the reported results from the Phase lla trial, and we believe the study results support a potential indication of VTX3232 in additional neurodegenerative diseases. We remain bullish on shares of $VTYX and reiterate our $14 12-month PT."

0 · Reply

LifeisaMeme Jun. 19 at 5:35 PM

$VTYX $RGLS $VIGL What kind of engineering did you study

0 · Reply

BinaryLogic Jun. 19 at 3:55 PM

$VTYX $RGLS $VIGL [Again]

0 · Reply

jacksparo Jun. 16 at 11:52 PM

$VERV Big pay day comes for whom the ones hold this one from my email few weeks ago!! Big move AH with buy out news! The second buy out in less than three weeks from Jack emails! Remember $VIGL And now VERV!

1 · Reply

Stocks4thought Jun. 16 at 8:03 PM

$ANIX Just like $VIGL $SGMT they rise- I believe stocks are so manipulated to the downside- to enable [positioning for huge gains- follow suit- https://nypost.com/2025/06/07/us-news/breakthrough-vaccine-could-eradicate-breast-cancer-by-2030/

1 · Reply

BinaryLogic Jun. 14 at 11:59 PM

$VTYX Look at $RGLS and $VIGL, then come to $VTYX and you will see that some investor(s) are consistently and continuously building here, methodically, taking the SP off of Overbought conditions then continuing to climb. Look at the product pipeline here: multiple phase-2/3 candidates across Crohn's, ulcerative colitis, Parkinson's and peridcarditis. Now-look at the financial statements. This Company has more than doubled over the last month and it is still valued under BV! Excellent acquisition target with 3-5X additional upside (IMO). https://ventyxbio.com/pipeline/

1 · Reply

Quantumup Jun. 12 at 7:15 PM

Piper Sandler, on June 9, reiterated $VTYX OW-$21 and said "we remain bullish on $VTYX's robust NLRP3 portfolio and believe these key readouts are de-risked given its straightforward MoA validated by approved IL-1ß agents." $VIGL - $SNY Piper Sandler additionally said in its note to investors:

0 · Reply

NancyPelosi____insider Jun. 12 at 5:35 PM

$CRDL $CPRX $CRMD $CRVO $VIGL

0 · Reply

Wolfmantis Jun. 5 at 9:36 PM

$SGMO its funny how a company like vigil $VIGL can get bought for 470 mil by sanofi and have a failed drug with no deep pipeline and a company like sangamo be sitting here with multiple phase 3 assets , multiple partnerships , multiple platforms and one of the deepest pipelines in genetics and not get a glimmer of a buyout. It's gotta be the poor management I'm 100% convinced .

3 · Reply

theirishreally Jun. 5 at 4:00 AM

$CHPT I listened to the call and feel that this is a good long term bet. I feel the company is doing better than expected in light of the interesting political situation in the US and is heading slowly in the right direction. I was in $RYCEY and $VIGL when the price had collapsed and saw similar wailing and gnashing of teeth. There is significant value in the subscriber model and contrary to some I think EVs are only going to grow. As the CEO mentioned there is a shortage of charging points in a number of markets.

3 · Reply

DonCorleone77 Jun. 4 at 11:08 AM

$VIGL Vigil Neuroscience provides update on Phase 2 IGNITE trial of iluzanebart Vigil Neuroscience announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. Iluzanebart demonstrated a favorable safety, tolerability and pharmacokinetic profile across both the 20 mg/kg and 40 mg/kg dose cohorts. The Phase 2 IGNITE trial showed no beneficial effects on biomarker or clinical efficacy endpoints with treatment of iluzanebart in ALSP patients. Based upon these results, the Phase 2 long-term extension study is being discontinued in accordance with the process previously disclosed.

0 · Reply

MOUNTAINDEW2 Jun. 3 at 8:16 PM

$VIGL bullshitt lying bastereds

0 · Reply

Market Cap	384.83M
Revenue (ttm)	0.00
Net Income (ttm)	-84.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	383,800
Avg Vol	1,680,870
Day's Range	N/A - N/A
Shares Out	47.69M
Stochastic %K	77%
Beta	3.34
Analysts	Hold
Price Target	$8.00